Vascular Medicine News

Healio | Cardiology Today has compiled a list of the topic headlines of August 2023 in cardiology.

After pooling individual-level data from 112 cohort studies, researchers determined that more than 50% of cases of CVD can be attributed to five modifiable risk factors — BMI, systolic BP, non-HDL, current smoking and diabetes.

Anakinra, an interleukin-1R antagonist, was shown to be a safe treatment in patients with acute myocarditis, but did not change the number of days free from complications compared with placebo, a speaker reported.

A new generation of obesity drugs is changing the treatment landscape for patients and providers, with options that can lead to weight loss unheard of just a few years ago.

HHS announced the first 10 drugs that will be subject to Medicare price negotiations.

In the STOPDAPT-3 trial, an aspirin-free strategy after PCI did not reduce major bleeding event risk compared with dual antiplatelet therapy, with data also suggesting a signal for excess coronary events, a speaker reported.

In the ONCO-DVT trial, patients with cancer and isolated distal deep vein thrombosis had fewer thrombotic events at 1 year with 12-month vs. 3-month edoxaban therapy, a finding that could change clinical guidance, according to a speaker.

Extended clopidogrel monotherapy after 9-to-12-month dual antiplatelet therapy reduced risk for adverse events in patients with ACS at increased bleeding and ischemic risk who underwent drug-eluting stent implantation, a speaker reported.

Immediate PCI of nonculprit lesions during index hospitalization for STEMI was shown to be noninferior with fewer adverse events vs. a staged strategy addressing the nonculprit lesions after successful primary PCI, a speaker reported.

Cardiometabolic comorbidities, such as hypertension, cardiac arrythmias and diabetes, are more common in adults with acromegaly than those without the condition, according to a systematic review and meta-analysis published in Pituitary.